Uveitis Risk with Slow Adalimumab Weaning Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr

2nd Opinions in Rheumatology https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU

Vamorolone: a New Steroid on the Horizon? Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases. It is a dissociated steroidal compound with reduced side effects, and in an animal model of inflammation has shown effective https://t.co/38WTOAuuJy

Summary of the updated BSR Axial Spondyloarthritis for biological and targeted synthetic DMARD guidelines 2025 @RheumatologyUK #axialspondyloarthritis Full paper available at: https://t.co/LytDiHjawi https://t.co/iaHzD1BQRe

📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF

Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies. View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY

In our latest episode, @deodhara takes us behind the scenes of his research on IV secukinumab in #AxSpA. Discover key findings from the INVIGORATE-1 study, how it’s shaping treatment options, & what’s next in AxSpA research. LISTEN NOW → https://t.co/2IBixQSdpO @ACR_Journals https://t.co/HzcJw0pzWI

43 days to the Lupus Congress 2025 in Toronto 🦋...see you soon! Abstract Sessions, Poster Tour Presentations, Plenary Sessions, Scientific Sessions, Debate Sessions, Patient Sessions, Fishbowl Discussion, and GALA DINNER on May 23!!! @LupusCongress https://t.co/MaWjyofnIz

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies Sponsored by UCB https://t.co/461bFRZwjw

Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG